Omniab, Inc. · NASDAQ:OABI
Omniab — 13th World Bispecific Summit, Boston 2022
16 slides from Omniab's conference presentation, Sep 21, 2022
Slide 1: High-Specificity OmniAb Antibodies for Bispecific Applications
1 High-Specificity OmniAb Antibodies for Bispecific Applications 13th World Bispecific Summit, Boston Christel Iffland, Ph.D. VP of Antibody Technologies September 21, 2022
Slide 2: The OmniAb Technology Suite
2 The OmniAb Technology Suite The only platform leveraging four-species ™ Robust solutions for bispecific antibodies Human frameworks with ultralong CDR-H3s ® Industry’s most diverse offering Proven success
Slide 3: Antibody Repertoires and Bispecific Antibodies
3 Antibody Repertoires and Bispecific Antibodies ACTIVE PROGRAMS CLINICAL PROGRAMS + + 19% Bispecific 33% 18% 63% Monospecific + 67% Combining sources provides partners even more diverse repertoires and new target access Common light chain techs being used for flexibility and bispecific program opti
Slide 4: Approved and Clinical Partner Bispecific Pipeline
4 Approved and Clinical Partner Bispecific Pipeline ONE APPROVED PRODUCT AND 10 ACTIVE CLINICAL OMNIAB-DERIVED ANTIBODIES Partner Program Source Animal Area Targets TECVAYLI® OmniRat Oncology BCMA x CD3 GEN1046 OmniRat Oncology PD-L1 x 4-1BB APVO436 OmniMouse Oncology CD123 x CD3 JNJ-67371244 OmniMo
Slide 5: Rodent Platforms
5 Rodent Platforms Light chain loci Heavy chain locus VL J CL VH DH JH EµCµCγ1 Cγ2b ε α • Endogenous Ig genes inactivated + Fully human LC Human V, D, J Rat constant • Expression of full human V gene diversity VJ C • Streamlined conversion into fully human VDJ C molecule mRNA Human Antibody Well-val
Slide 6: OmniChicken Platform
6 OmniChicken Platform POWERED BY EVOLUTION 300 million years Primordial target gene 95 million years Chicken orthologue Murine orthologue Human orthologue Greater evolutionary distance yields greater immunogenicity and more antibody diversity
Slide 7: Engineering of Ig Loci
7 Engineering of Ig Loci ADAPTATION TO CHICKEN GENE CONVERSION PROCESS Gene conversion Engineered locus Germline VH3-23 VK3-15 or VL1-44 // CDR-focused diversity Gene conversion Diversified B-cells Human V’s selected for: // • High expression level, stability, ubiquity // • High sequence diversity i
Slide 8: Common Light Chain Platforms
8 Common Light Chain Platforms STANDARD IGG FORMAT TO DE-RISK DOWNSTREAM DEVELOPMENT1 OF BISPECIFIC MABS Rearranged IgVK3-15/JK1 IgKC IgVK3-15/JK1 JK2-5 // Rearranged human VK3-15 light chain “Germlining” human VK3-15 light chain combined with diversifying heavy chain combined with diversifying heav
Slide 9: OmnidAb™: Heavy Chain Only Transgenic Chickens
9 OmnidAb™: Heavy Chain Only Transgenic Chickens HCO STRATEGY USING TRUNCATED LIGHT CHAIN (TLC) tLC transgene tLC Chicken VH sdAb (hu Fc) tLC transgene + tLC human VHH sdAb VHH transgene (hu Fc) • Normal chicken heavy chain can express as VH alone • VHH transgene in development
Slide 10: Ultralong CDRH3s Create Novel Binding Domains
10 Ultralong CDRH3s Create Novel Binding Domains UNIQUE STRUCTURAL FEATURES OF ULTRALONG H3 ANTIBODIES CDRH3 Human Cow • Novel structure may enable targeting epitopes unreachable by standard antibodies • Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies™ Stanfield,
Slide 11: Picobodies™ as Building Blocks for Novel Therapeutics
11 Picobodies™ as Building Blocks for Novel Therapeutics
Slide 12: OmniAb Antibody Repertoires
12 OmniAb Antibody Repertoires OPTIONS AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES Structural and Benefits for therapeutics Host V genes immunological features discovery and development Full human V gene diversity Diverse V gene usage and mixed genetic Widely accessible and flexible workflows Ch
Slide 13: Screening Technology: xPloration®
13 Screening Technology: xPloration® 1 | Loading 2 | Assay + Machine Vision 3 | Recovery & Single-Cell NGS Bright Field Enzymatic Fluorescent Reactions Antibodies 1.5 million, 40 µm 6 million, 20 µm Label-free Enzyme Inhibitions Cell Surface Binding GFP Immune Reporter Activation cAMP Signaling 20 h
Slide 14: Leveraging Biological Intelligence with Computational Tools
14 Leveraging Biological Intelligence with Computational Tools Biological Intelligence Model-aided • Antibody homology modeling optimization • Computational antibody optimization • Sequence liability assessment In silico • Comparison to clinical antibodies developability • Structure-based calculatio
Slide 15: The OmniAb Platform
15 The OmniAb Platform Technology offering addresses the most critical challenges of antibody discovery
Slide 16: Thank You to the OmniAb Team!
16 THANK YOU TO THE OMNIAB TEAM! www.OmniAb.com